samedan logo
 
 
spacer
home > pmps > winter 2020 > smart packaging: increasing therapeutic adherence
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Smart Packaging: Increasing Therapeutic Adherence




Failure to adhere to medicinal treatment regimens is arguably the world’s biggest therapeutic challenge. The R&D spend on the discovery and extension of the drug pipeline in 2018 was reported at $179 billion, some 21.6% of sales (1). Given that typical adherence levels on average sit around 50% non-adherence to long-term therapy for chronic illnesses, intentional and unintentional medication non-adherence signifies a prevalent and persistent healthcare problem, and it is frankly amazing that greater effort and spend is not directed to addressing this global crisis.

More specifically in terms of the human impact, nearly half of all adults and approximately 8% of children (aged 5-17 years) worldwide have a chronic condition.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


In a career that has spanned over three decades, Chris Waterhouse has provided packaging and supply chain technical expertise and innovation insight to some of world’s leading pharma, agrochemical, and petrochemical companies. Chris is Managing Director of iDi Pac and former Chairman of the UK Packaging Society, the “home of packaging professionals”, which represents packaging professionals across the UK and overseas. Widely recognised as the ‘go-to guy’, Chris is much sought after across the packaging and supply chain industry, and is an acclaimed speaker at business conferences and industry events – well known for his technical innovations, practical insights, and leading-edge thinking.
Print this page
Send to a friend
Privacy statement
News and Press Releases

X-Chem Acquires ComInnex

WALTHAM, Mass.; Oct. 25, 2021 (Business Wire) – X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement